Latest type of biological therapy, monoclonal antibodies, tipped as having huge potential in China
Deutsche Bank analysts predict mAbs market to see 24pc compound annual growth from 2017 to 2022 after the first major approval in 2018
Deutsche Bank analysts expect to see substantial growth opportunities in China’s monoclonal antibodies (mAbs) market in the coming five years, naming 3SBio and Shanghai Fosun Pharmaceutical as among the first-movers in the sector.
Monoclonal antibodies are a type of biological therapy used in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, and osteoporosis. Monoclonal antibody are target specific in action, by not affecting other cells of the body thus restores the immune system.
The latest data from Deutsche Bank predicts that as a distinctive therapeutic modal, the mAbs market expects to see a 24 per cent compound annual growth rate from 2017 to 2022 after the first major biosimilar approval in 2018. The market will reach 36 billion yuan in 2022 from 10 billion yuan in 2016, the data from Deutsche Bank showed.
The rising market is driven by “rising incidences, reimbursement expansion, and discount pricing by incoming biosimilars”, said Deutsche Bank analysts Jack Hu and Linc Yiu in their latest report.
And the market demand is strengthening.
The term biosimilars refers to almost identical copies of an original product, manufactured by a different company.
